Clinical Trial Update: Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating teclistamab plus autologous lymphocyte infusion for relapsed/refractory multiple myeloma. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Autologous lymphocyte infusion (autologous lymphocyte infusion)
• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Multiple Myleoma, Multiple Myeloma in Relapse | Phase 2 | Status: NOT_YET_RECRUITING